Current Report Filing (8-k)
April 13 2022 - 8:01AM
Edgar (US Regulatory)
0001388320
false
0001388320
2022-04-07
2022-04-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 7, 2022
ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36374 |
|
74-2963609 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
275
Madison Avenue, 7th
Floor, New York,
NY 10016
(Address of Principal Executive Offices)
Registrant’s telephone number: (646) 677-3870
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
ATNM |
|
NYSE American |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On April 7, 2022, Actinium Pharmaceuticals,
Inc. (the “Company”) entered into a license and supply agreement (the “License Agreement”)
with Immedica Pharma AB (“Immedica”), pursuant to which Immedica licensed the exclusive product rights for commercialization
of Iomab-B (I-131 apamistamab) in the European Economic Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain,
Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya. Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia,
Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company
is entitled to an upfront payment of $35 million from Immedica. Under the terms of the License Agreement, the Company is eligible to receive
aggregate regulatory and commercial milestone payments of up to approximately $417 million, subject to future currency exchange rates.
Additionally, the Company is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries
that may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and
the manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.
The foregoing description of the License Agreement
is not complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which will be filed
as an exhibit to the Company’s Quarterly Report on form 10-Q for the quarter ended June 30, 2022.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Actinium Pharmaceuticals, Inc. |
|
|
Date: April 13, 2022 |
/s/ Sandesh Seth |
|
Name: Sandesh Seth |
|
Title: Chairman and Chief Executive Officer |
2
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Sep 2023 to Sep 2024